ERNA — Ernexa Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Eterna Therapeutics Completes Strategic Financial Restructuring With The Aim To Accelerate Its Developmental Activities And Long-Term Success
Brief: Factor Bioscience And Eterna Therapeutics Announce Exclusive License And Collaboration Agreement To Accelerate Cell Therapy Development For Oncology, Autoimmune, And Rare Diseases
Brief: Eterna Therapeutics And Factor Bioscience Announce Exclusive License And Collaboration Agreement To Accelerate Cell Therapy Development For Oncology, Autoimmune, And Rare Diseases
Brief: Eterna Therapeutics Enters Into License & Collaboration Agreement With Factor Bioscience
Brief: Eterna Therapeutics Received A Notice From Nasdaq Stating That Co Is Not In Compliance With Nasdaq Listing Rule 5550(B)(1)
Brief: Eterna Therapeutics Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Eterna Therapeutics Names Sanjeev Luther As CEO
Brief: Eterna Therapeutics Inc - Co Entered Into An Exclusive Amended And Restated License Agreement With Factor Bioscience Limited
Brief: Eterna Therapeutics Announces Initiation Of Development Activities For Hypoimmune Pluripotent Cell Line For Neurology Indications Under Partnership With Lineage Cell Therapeutics
Brief: Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke To Board Of Directors
Brief: Eterna Therapeutics Announces Completion Of $8.7 Mln Of Convertible Debt Financing
Brief: Eterna Therapeutics Appoints Megan Yung As Chief Strategy Officer, General Counsel
U.S. STOCKS ON THE MOVE-Icahn Enterprises, T Rowe Price, Dell Technologies
U.S. STOCKS ON THE MOVE-Sysco, Gartner, Molson Coors Beverage
Eterna Therapeutics rises on acquisition of immuno-oncology platform
Brief: Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform From Exacis Biotherapeutics
Brief: Eterna Therapeutics & Lincoln Park Capital Enter Into Common Stock Purchase Agreement For Up To $10 Mln
Brief: Eterna Therapeutics Files Prospectus Relates To Offering, Resale From Time To Time By Selling Stockholder Of Up To 685,714 Shares Of Common Stock
Brief: Eterna Therapeutics Inc Reports Net Loss For Q4 Of 2022 Of $4.5 Million, Or $1.24 Per Share